A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone and in combination with L19-IL2 as a treatment of metastatic FAP-positive solid tumors.
PH-FAPLU-02-23
Phase 1 other active
Quick answer
A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone and in combination with L19-IL2 as a treatment of metastatic FAP-positive solid tumors. for Patients with advanced/metastatic FAP-positive tumors is a Phase 1 program (other) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Philogen S.p.A.
- Indication
- Patients with advanced/metastatic FAP-positive tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active